Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Viewers also liked
Similar to Bacterial animation and management
Similar to Bacterial animation and management (20)
More from samirelansary
More from samirelansary (20)
Recently uploaded
Recently uploaded (20)
Bacterial animation and management
- 1. BACTERIAL ANIMATION AND MANAGEMENT 2 SAMIR EL ANSARY ICU PROFESSOR AIN SHAMS CAIRO elansarysamir@yahoo.com
- 2. Global Critical Care https://www.facebook.com/groups/1451610115129555/#!/groups/145 1610115129555/ Wellcome in our new group ..... Dr.SAMIR EL ANSARY
- 4. Health Care-Associated Infection (HAI) * Hospital acquired infection * Nosocomial infection
- 5. Health Care-Associated Infection (HAI) 3 • Localized or systemic condition resulting from an adverse reaction to the presence of an infectious agent(s) or its toxin(s) • There must be no evidence that the infection was present or incubating at the time of admission to the hospital • For most bacterial infections, this means that the infection usually become evident 48 hours (the typical incubation period) or more after admission
- 6. Health Care-Associated Infection (HAI) 4 Because the incubation period varies with - the type of pathogen - the patient’s underlying condition Each infection must be assessed individually for evidence that links to the hospitalization
- 7. Health Care-Associated Infection (HAI) 5 May be caused by infectious agents from • Endogenous sources :- skin, nose, GI tract or vagina that are normally inhabited by microorganisms •Exogenous sources :- patient care personnel, visitors, patient care equipment, medical devices or health care environment
- 8. BACTERIA Acinetobacter baumannii Pseudomonas aeruginosa Klebsiella pneumoniae Staphylococcus aureus (MRSA) No culture & no growth NOSOCOMIAL BACTERIA ISOLATED FROM VAP VAP : Ventilator associated pneumonia 8
- 10. Cell Wall of Gram-Negative Bacteria 12
- 11. Physiologic Action of LPS from the Gram- Negative Cell Wall 13
- 12. Animation :Physiologic Action of LPS 14
- 13. Antibacterial drugs % Susceptibility Trimethoprim- sulfamethoxazole 44 Gentamicin 79 Amikacin 99 Percentage of Susceptible E. coli Isolated from All Clinical Specimens 15
- 14. Antibacterial drugs % Susceptibility Trimethoprim-sulfamethoxazole 44 Gentamicin 79 Amikacin 99 Amoxicillin-clavulanic acid 85 Percentage of Susceptible E. coli 15 Clavulanic acid : b-lactamase inhibitor
- 15. Antibacterial drugs % Susceptibility Trimethoprim-sulfamethoxazole 44 Gentamicin 79 Amikacin 99 Amoxicillin-clavulanic acid 85 Cefotaxime 96 Ceftazidime 96 Cefepime 98 Imipenem 100 Meropenem 100 Ofloxacin 51 Percentage of Susceptible E. coli 15
- 16. Extended-Spectrum b–Lactamase (ESBL) •penicillins, cephalosporins b-lactamase inhibitor :- clavulanic acid 17
- 17. Antibacterial drugs % Susceptibility Trimethoprim-sulfamethoxazole 25 Gentamicin 35 Amikacin 95 Amoxicillin-clavulanic acid 47 Cefotaxime 0 Cefoperazone-sulbactam 0 Cefepime 0 Imipenem 100 Meropenem 100 Ofloxacin 18 Percentage of Susceptible E. coli ESBL producing 16
- 19. Phagocytosis Blocked by Capsule (Animation) 19
- 20. •Enterotoxin) •Urinary tract infection (UTI) K. pneumoniae 20 K. pneumoniae producing ESBL
- 21. • Aerobic gram-negative bacilli, non-spore forming • Grape-like odor •Saprophyte (soil, water) • Pyocyanin pigment •Intestinal flora Pseudomonas aeruginosa •Opportunistic pathogen 21
- 22. 23
- 23. Virulence factors Alginate (slime layers, biofilm) (polymer of mannuronic & glucuronic acid) • Prevent phagocytosis • Adhere to epithelial cells 24
- 24. Clinical manifestation of P. aeruginosa infections 25
- 25. Antibacterial drugs % Susceptibility Colistin 100 Gentamicin 71 Amikacin 76 Piperacillin-tazobactam 83 Cefoperazone-sulbactam 69 Ceftazidime 67 Cefepime 69 Imipenem 69 Meropenem 72 Ciprofloxacin 69 Percentage of Susceptible P. aeruginosa 27
- 26. Acinetobacter • Aerobic gram-negative coccobacilli, non-spore forming • > 25 species •A. baumannii is the most common cause of ventilator- associated pneumonia (VAP) •Opportunistic pathogen
- 27. A. baumannii Clinical manifestation of A. baumannii infection 1.Hospital-acquired pneumonia especially VAP 2.Community-acquired pneumonia :The source of infection may be throat carriage, which occurs in 10% of community residents with excessive alcohol consumption 3.Bloodstream infection & endocarditis 4.Skin/soft tissue infection 5.UTI 6.Meningitis 29
- 28. Antibacterial drugs % Susceptibility Colistin 99 Gentamicin 25 Amikacin 28 Cefoperazone-sulbactam 31 Ceftazidime 23 Cefepime 21 Imipenem 26 Meropenem 27 Ciprofloxacin 23 Percentage of Susceptible A. baumannii 30
- 29. A. baumannii Persistence in the hospital environment : 3 days to 5 months 1. Resistance to major antimicrobial drugs 2. Resistance to desiccation 3. Resistance to disinfectant Three factors contributing to the persistence : 31
- 30. STAPHYLOCOCCUS
- 33. 3. Hyaluronidase (Spreading factor) Hyaluronidase digests hyaluronic acid, the “glue” that holds cells together 37
- 34. Clinical manifestation of S. aureus infection 38
- 35. Antibacterial drugs % Susceptibility Trimethoprim-sulfamethoxazole 99 Oxacillin 100 Erythromycin 93 Clindamycin 93 Vancomycin 100 Fosfomycin 88 Percentage of Susceptible S. aureus (MSSA) 39
- 36. 40
- 37. Antibacterial drugs % Susceptibility Trimethoprim-sulfamethoxazole 9 Oxacillin 0 Erythromycin 1 Clindamycin 2 Vancomycin 100 Fosfomycin 76 Percentage of Susceptible S. aureus (MRSA) 42
- 38. Enterococci • Gram-positive cocci in chain 44
- 39. Enterococci • Gram-positive cocci in chain • Commensals of the GI tract of humans & animals • Diseases : • Consist of 16 species :- E. faecalis, E. faecium - Urinary tract infection (UTI) - Bacteremia, endocarditis 44
- 40. Antibacterial drugs % Susceptibility Tetracycline 6 Penicillin 9 Ampicillin 10 Vancomycin 99 Levofloxacin 11 Percentage of Susceptible E. faecium 45
- 42. VRE Transmission Health care settings Community settings Colonization of discharged patients with VRE Discharge Colonization of individuals Colonization of patient Admission Colonization & transmission among food producing animals effects by Avoparcin / Glycopeptide Ingestion Household transmission Colonization or infection identified due to selective antimicrobial pressure and/or underlying illness Health care transmission Worker hands Environment 48
- 43. BACTERIA Duration of persistance (range) Acinetobacter spp. 3 days to 5 months Clostridium difficile (spores) 5 months Escherichia coli 1.5 hours -16 months Enterococcus spp.including VRE and VSE 5 days - 4 months Klebsiella spp. 2 hours to >30 months Mycobacterium tuberculosis 1 day - 4 months Pseudomonas aeruginosa 6 hours -16 months; on dry floor : 5 weeks Staphylococcus aureus, including MRSA 7 days - 7 months Persistence of nosocomial bacteria on dry inanimate surfaces 49
- 44. Contaminated inanimate surface Susceptible patient Hands of healthcare worker Direct transmission Common Modes of Transmission from Inanimate Surfaces to Patients 50 Compliance in hand hygiene:~50%
- 45. 1. Transduction 2. Conjugation 3. Transformation
- 46. Attachment 1 2 3 Phage DNA is injected into bacterial cell Multiplication Assembly with some mistake Generalized Transduction by Lytic Phage (1)
- 47. Generalized Transduction (2) Bacterial cell is broken to release progeny phages 4 5 Phage carrying donor DNA infects another bacterium (recipient) 53
- 48. Generalized Transduction (3) 6 7 Genetic exchangeDonor bacterial DNA is injected into recipient cell Any piecies of the DNA of the donor cell can be transferred 3 54
- 50. Conjugation by Sex Pilus 56
- 52. Transformation : transfer naked DNA
- 54. GOOD LUCK SAMIR EL ANSARY ICU PROFESSOR AIN SHAMS CAIRO elansarysamir@yahoo.com Global Critical Care https://www.facebook.com/groups/1451610115129555/#!/groups/145 1610115129555/ Wellcome in our new group ..... Dr.SAMIR EL ANSARY